INTRODUCTION {#sec1}
============

The time for ventricular depolarization and repolarization is measured on the surface electrocardiogram (ECG) as the time from the start of the Q wave to the end of the T wave. Prolonged repolarization is recorded on ECG as lengthening of the QT interval ([@B1]). This condition is considered to increase the risk for ventricular arrhythmias and the potentially fatal "torsades de pointes" (TdP). Ventricular repolarization is mediated mostly by the outflow of potassium (K^+^) from the myocytes. Attenuation of the voltage-dependent K^+^ channels\' ability to repolarize can prolong the QT interval and create the conditions for TdP.

There is very little knowledge about how acute tuberculosis (TB) affects the QT interval or about the potential for antituberculosis treatments to affect ventricular repolarization. With prospects of having them added to the antituberculosis armory of drugs, drugs belonging to the fluoroquinolone (FQ) family have attracted attention, as they can variably affect ventricular repolarization ([@B2]). These drugs have different affinities for binding to the rapid component of the delayed-rectifier current I~Kr~, which is expressed by the human ether-a-go-go-related gene (hERG) ([@B3]). In particular, it has been suggested that compounds such as gatifloxacin and moxifloxacin, both considered in antituberculosis regimens, which have a methoxy substitution at position C-8, might inhibit hERG at therapeutically achievable concentrations ([@B4]).

Establishing the risk for QT prolongation associated with the use of a drug is not straightforward. The length of the QT interval varies during the day and from day to day and with gender and age and is influenced by potassium levels, body temperature, heart rate (HR), and factors such as disease and drugs. It is customary to introduce a correction factor to account for the effect of the heart rate (heart rate-corrected QT \[QTc\]). The correction factor is introduced to make the QT independent of the heart rate, hence the need for the slope of the regression line to be as close to zero as possible when the QT is plotted against the heart rate. The QTc is calculated by dividing the QT by RR (calculated as 60/heart rate). The International Conference for Harmonization (ICH) recommends analyzing the QT using the Bazett and the Fridericia corrections (QTcB and QTcF, respectively), which use fixed exponents of 0.5 and 0.33, respectively, for the RR, and exploring other corrections whenever appropriate. The Bazett correction QTcB (QT/RR^0.5^) is considered most suited for HRs of 60 to 100 beats per min (bpm) (it undercorrects if HR is \<60 and overcorrects if HR is \>100 bpm); the Fridericia formula QTcF (QT/RR^0.33^) is generally regarded as more appropriate outside this range. Various other corrections exist. Population-based corrections are also recommended for specific conditions ([@B5], [@B6]). There is no information on the appropriateness of these corrections in patients with pulmonary tuberculosis (PTB), i.e., how good they are in making the QT interval independent of the heart rate.

We analyzed the QT of patients with PTB enrolled in a randomized trial with a noninferiority design comparing the standard 6-month treatment to a gatifloxacin-containing 4-month regimen (the OFLOTUB trial \[ClinicalTrials.gov registration no. NCT00216385\]) ([@B7]). We also evaluated the effect of exposure, expressed as maximum concentration of drug in serum (*C*~max~) of the individual drugs of both treatment arms, in the patients who participated in a pharmacokinetic substudy (nested pharmacokinetic/pharmacodynamic \[PK/PD\] study).

RESULTS {#sec2}
=======

Patients\' characteristics. {#sec2-1}
---------------------------

Of the 1,692 patients in the intention-to-treat (ITT) population, 1,686 (99.6%) were eligible for the correction factor analysis of QT at baseline (flow diagram in [Fig. 1](#F1){ref-type="fig"}). Mean age was 30.7 years, 27% were female, 18% were HIV positive, 51% had cavitation, and 25% had a temperature of \>37.7°C ([Table 1](#T1){ref-type="table"}).

![Study flow diagram.](zac0071762750001){#F1}

###### 

Baseline demographics and clinical variables for patients in the correction factor analysis (*n* = 1,686) and the comparison of QTc by treatment arm (*n* = 1,602)

  Demographic characteristic or clinical variable                 Correction factor analysis (*n* = 1,686)        Between-arm comparison (*n* = 1,602)                 
  --------------------------------------------------------------- ----------------------------------------------- -------------------------------------- ------------- -------------
  No. of patients from country (%)                                                                                                                                     
      Benin                                                       158 (18.7)                                      158 (18.8)                             150 (18.7)    151 (18.9)
      Guinea                                                      219 (25.9)                                      225 (26.7)                             216 (26.9)    213 (26.7)
      Kenya                                                       100 (11.8)                                      97 (11.5)                              100 (12.4)    95 (11.9)
      Senegal                                                     178 (21.1)                                      180 (21.4)                             154 (19.1)    163 (20.4)
      South Africa                                                190 (22.5)                                      181 (21.5)                             184 (22.9)    176 (22.1)
  Mean age, yr (SD)                                               30.8[^*a*^](#T1F1){ref-type="table-fn"} (9.1)   30.6 (9.0)                             30.8 (9.1)    30.6 (8.9)
  No. female (%)                                                  229 (27.1)                                      232 (27.6)                             215 (26.7)    224 (28.1)
  No. HIV positive (%)[^*b*^](#T1F2){ref-type="table-fn"}         147 (17.5)                                      156 (18.8)                             141 (17.6)    150 (18.9)
  No. with cavitation (%)[^*c*^](#T1F3){ref-type="table-fn"}      438 (52.0)                                      417 (50.0)                             413 (51.5)    394 (49.8)
  Mean heart rate (SD)[^*d*^](#T1F4){ref-type="table-fn"}         95.6 (17.4)                                     95.1 (17.8)                            95.6 (17.5)   95.2 (17.5)
  No. with temp \>37.7°C (%)[^*e*^](#T1F5){ref-type="table-fn"}   216 (25.6)                                      198 (23.6)                             201 (25.0)    187 (23.5)
  Mean BMI (SD)[^*f*^](#T1F6){ref-type="table-fn"}                17.4 (4.9)                                      17.5 (5.0)                             17.3 (4.9)    17.5 (5.0)

Age not known for *n* = 1 in the test arm.

HIV status unknown in the correction factor analysis for *n* = 11 (*n* = 5 in the test arm, *n* = 6 in the control arm) and in the between-arm comparison for *n* = 10 (*n* = 5 in the test arm, *n* = 5 in the control arm).

Cavitary status unknown in the correction factor analysis for *n* = 10 (*n* = 3 in the test arm, *n* = 7 in the control arm) and in the between-arm comparison for *n* = 9 (*n* = 2 in the test arm, *n* = 7 in the control arm).

Heart rate unknown in the between-arm comparison for *n* = 4 (*n* = 2 in the test arm, *n* = 2 in the control arm).

Temperature unknown in the correction factor analysis for *n* = 4 (*n* = 1 in the test arm, *n* = 3 in the control arm) and in the between-arm comparison for *n* = 3 (*n* = 1 in the test arm, *n* = 2 in the control arm).

BMI, body mass index.

Heart rate and temperature. {#sec2-2}
---------------------------

Median heart rate decreased progressively from 96/min at baseline throughout treatment to reach 71 at the end of treatment. Median baseline body temperature was 37.2°C and decreased to approximately 36.5°C on treatment. The percentage of participants with temperatures of \>37.7°C fell over follow-up to 2.7% (43/1,582) and 2.4% (37/1,539) at months 1 and 2 after the start of TB treatment, respectively, and to 0.7% (10/1,445) at the end of treatment ([Table 2](#T2){ref-type="table"}).

###### 

Heart rate and temperature during the treatment phase, restricted to samples with data available for the correction analysis

  Sampling time                                         Heart rate   Temp (°C)   \% (no./total no.) of patients with temp of \>37. 7°C                               
  ----------------------------------------------------- ------------ ----------- ------------------------------------------------------- ------ ------------ ------- ------------------
  Baseline                                              96           83--106     1,686                                                   37.2   36.6--37.7   1,682   24.6 (414/1,682)
  Month 1                                               81           71--95      1,562                                                   36.6   36--37       1,582   2.7 (43/1,582)
  Month 2                                               78           68--90      1,512                                                   36.5   36--36.9     1,512   2.4 (37/1,539)
  End of treatment[^*a*^](#T2F1){ref-type="table-fn"}   71           62--81      1,402                                                   36.4   36--36.9     1,445   0.7 (10/1,445)

Month 4 (gatifloxacin) or month 6 (control).

IQR, interquartile range.

Correction factors. {#sec2-3}
-------------------

In these patients with active PTB about to initiate treatment, the uncorrected QT increased with the heart rate overall (coefficient −202.7; 95% confidence interval \[CI\], −209.6 to −195.9; adjusted *R*^2^ = 0.67) ([Table 3](#T3){ref-type="table"}).

###### 

Linear regression coefficients (gradient and intercept) for uncorrected QT and Bazett (QTcB), Fridericia (QTcF), and new (QTcTB) corrections versus 1-RR at baseline (randomization), 1 and 2 months from start of treatment, and end of treatment

  QT and parameter                                    Value at sampling time (*n*):                                                       
  --------------------------------------------------- ------------------------------- ------------------------- ------------------------- -------------------------
  Uncorrected QT                                                                                                                          
      Gradient (95% CI)                               −202.7 (−209.6, −195.9)         −162.3 (−168.8, −155.8)   −154.5 (−161.1, −148.0)   −134.4 (−141.3, −126.7)
      Intercept (95% CI)                              403.8 (401.2, 406.3)            396.3 (394.4, 398.3)      395.1 (393.4, 396.9)      395.1 (391.9, 395.0)
      *R*^2^                                          0.67                            0.61                      0.59                      0.48
  QTcB                                                                                                                                    
      Gradient (95% CI)                               51.8 (43.5, 60.1)               80.8 (73.5, 88.1)         80.8 (73.6, 88.0)         90.0 (82.3, 97.7)
      Intercept (95% CI)                              397.1 (394.1, 400.2)            394.1 (392.0, 396.3)      394.5 (392.5, 396.4)      394.7 (393.0, 396.3)
      *R*^2^                                          0.08                            0.23                      0.24                      0.27
  QTcF                                                                                                                                    
      Gradient (95% CI)                               −46.3 (−54.1, −38.5)            −9.8 (−16.8, −2.8)        −5.5 (−12.5, 1.4)         9.7 (2.2, 17.2)
      Intercept (95% CI)                              401.0 (398.1, 403.9)            395.4 (393.3, 397.4)      394.9 (392.0, 396.7)      394.1 (392.5, 395.7)
      *R*^2^                                          0.075                           0.005                     0.002                     0.005
  QTcTB[^*b*^](#T3F2){ref-type="table-fn"}                                                                                                
      Gradient (95% CI)                               −2.9 (−10.9, 5.1)               30.7 (23.6, 37.8)         33.3 (26.2, 40.3)         46.0 (38.4, 53.6)
      Intercept (95% CI)                              399.5 (396.5, 402.4)            394.9 (392.8, 397.0)      394.7 (392.8, 396.6)      394.3 (392.7, 395.9)
      *R*^2^                                          0.000                           0.044                     0.053                     0.092
  QTcB, % (no.)                                                                                                                           
      \>450                                           5.5 (93)                        7.0 (109)                 6.7 (101)                 6.3 (88)
      \>480                                           0.3 (5)                         1.22 (19)                 1.2 (18)                  1.1 (16)
      \>500                                           0.1 (2)                         0.7 (11)                  0.5 (8)                   0.2 (3)
  QTcF, % (no.)                                                                                                                           
      \>450                                           0.24 (4)                        1.7 (27)                  1.3 (20)                  2.2 (31)
      \>480                                           0.06 (1)                        0.5 (8)                   0.3 (5)                   0.6 (8)
      \>500                                           0 (0)                           0.1 (2)                   0.2 (3)                   0.3 (4)
  QTcTB,[^*b*^](#T3F2){ref-type="table-fn"} % (no.)                                                                                       
      \>450                                           0.89 (15)                       2.4 (38)                  2.7 (41)                  3.3 (46)
      \>480                                           0.12 (2)                        0.6 (10)                  0.5 (8)                   0.78 (11)
      \>500                                           0.06 (1)                        0.51 (8)                  0.2 (3)                   0.29 (4)

Month 4 (gatifloxacin) or month 6 (control).

Correction factor, 0.4081 (95% CI, 0.3949, 0.4213).

At baseline, neither the Bazett nor the Fridericia correction was optimal; QTcB tended to undercorrect (gradient, 51.8; 95% CI, 43.5, 60.1) and QTcF tended to overcorrect (gradient, −46.3; 95% CI, −54.1, −38.5) the QT ([Fig. 2](#F2){ref-type="fig"}; [Table 3](#T3){ref-type="table"}). The nonlinear model estimated the correction factor to be 0.4081 (95% CI, 0.3949, 0.4213) (QTcTB), in between the Bazett and Fridericia correction factors. This correction factor was independent of the country, sex, and presence or absence of cavitation ([Fig. 3](#F3){ref-type="fig"}).

![Plot of uncorrected data and regression line and regression lines for Bazett-corrected, Fridericia-corrected, and new-corrected QT (QTc-TB), using data at baseline (*n* = 1,686). QT unc-obs, QT uncorrected observed data; QT uncorrected, uncorrected regression line; QTc-F, Fridericia-corrected regression line; QTc-B, Bazett-corrected regression line; QTc-TB, regression line corrected using correction factor of 0.4081.](zac0071762750002){#F2}

![Plot of uncorrected data and QTcTB (0.4081)-corrected regression line against 1-RR (where RR = 60/heart rate), using data at baseline, by country, sex, and cavitation status.](zac0071762750003){#F3}

Applying the Bazett and Fridericia corrections and the new correction factor to QT data measured 1 and 2 months after the start of TB treatment and at the end of treatment (month 4 in the test arm and month 6 in the control arm) showed the QTcF to be a better correction, with the gradient coefficient close to zero ([Table 3](#T3){ref-type="table"}).

Between-treatment comparison. {#sec2-4}
-----------------------------

The QTcF was therefore applied for between-treatment comparisons. A total of 1,602 patients contributed to these analyses ([Fig. 1](#F1){ref-type="fig"}). Baseline characteristics were similar between the two treatment arms ([Table 1](#T1){ref-type="table"}).

The peak QTcF value during follow-up was \>480 ms in 21 patients overall: 0.9% (7/804) and 1.8% (14/798) in the test and control arms, respectively ([Table 3](#T3){ref-type="table"}). There were nine occasions of QTcF being \>500 ms ([Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}). Five occurred in the test arm (0.6%) at month 1 (506 and 514 ms), month 2 (518 ms), and month 4 (502 and 511 ms), and four occurred in the standard treatment arm (0.5%) at month 2 (510 and 517 ms) and month 6 (507 and 569 ms). The risk differences for QTcF of \>480 ms and \>500 were −0.9% (95% CI, −2.0% to 2.3%; *P* = 0.12) and 0.1% (95% CI, −0.6% to 0.9%; *P* = 0.75), respectively, between the test and control arms. Overall, 107 (6.7%) patients had a peak measurement change from baseline of \>60 ms, with no difference between the two treatment arms (adjusted difference, 0.7%; 95% CI, −1.5% to 3.0%; *P* = 0.53).

###### 

Comparison of on-treatment Fridericia correction QT values by study arm

  Parameter and unit of measurement                 Test (*n* = 804)   Control (*n* = 798)   Difference (95% CI)[^*e*^](#T4F5){ref-type="table-fn"}     *P* value
  ------------------------------------------------- ------------------ --------------------- ---------------------------------------------------------- -----------
  Peak value in follow-up, mean (SD), ms            407.2 (23.3)       404.5 (25.3)          2.6 (0.2, 4.9)                                             0.030
      Change from baseline                          22.9 (26.2)        19.1 (28.1)           3.8 (1.1, 6.4)                                             0.005
  Peak value in follow-up, % (*n*)                                                                                                                      
      \>450 ms[^*a*^](#T4F1){ref-type="table-fn"}   4.3 (35)           4.4 (35)              **0.2 (−1.6, 2.0)**                                        0.83
      \>480 ms[^*b*^](#T4F2){ref-type="table-fn"}   0.9 (7)            1.8 (14)              **−0.9 (−2.0, 2.3%)**[^*d*^](#T4F4){ref-type="table-fn"}   0.12
      \>500 ms[^*c*^](#T4F3){ref-type="table-fn"}   0.6 (5)            0.5 (4)               **0.1 (−0.6, 0.9)**[^*d*^](#T4F4){ref-type="table-fn"}     0.75
      Change from baseline, \>60 ms                 7.0 (56)           6.4 (51)              **0.7 (−1.5, 3.0)**                                        0.53

Timing of peak value of \>450 ms: test arm, *n* = 12, 10, and 13 at month 1, month 2, and end of treatment, respectively; control arm, *n* = 15, 9, and 24 at month 1, month 2, and end of treatment, respectively.

Timing of peak value of \>480 ms: test arm, *n* = 3, 1, and 3 at month 1, month 2, and end of treatment, respectively; control arm, *n* = 5, 4, and 5 at month 1, month 2, and end of treatment, respectively.

Timing of peak value of \>500 ms: test arm, *n* = 2, 1, and 2 at month 1, month 2, and end of treatment, respectively; control arm, *n* = 0, 2, and 2 at month 1, month 2, and end of treatment, respectively.

Not adjusted for country.

Values shown in bold indicate risk difference (95% CI).

The overall mean peak QTc value was moderately higher in the test than in the control arm (adjusted mean difference, 2.6 ms \[95% CI, 0.2, 4.9\]; *P* = 0.030). The mean (95% CI) QTcF values at baseline, month 1, month 2, and end of treatment were 384.7 ms (383.2 to 386.1), 394.2 ms (392.6 to 395.7), 395.7 ms (394.1 to 397.3), and 395.9 ms (394.2 to 397.5) for the test arm and 385.1 ms (383.6 to 386.6), 391.6 ms (390.1 to 393.2), 391.7 ms (390.1 to 393.3), and 394.9 ms (393.1 to 396.7) for the control arm, respectively ([Fig. 4](#F4){ref-type="fig"}).

![Mean and 95% confidence interval (CI), by test and control arm, of QTcF values at baseline, months 1 and 2, and end of treatment (months 4 and 6, respectively).](zac0071762750004){#F4}

Drug levels. {#sec2-5}
------------

Pharmacokinetic measures were available for 291 patients at month 1 (144 and 147, respectively, in the test and control arms). The *C*~max~, time to maximum concentration of drug in serum (*T*~max~), and area under the concentration-time curve (AUC) achieved by the individual drugs in the two treatment arms are summarized in [Table 5](#T5){ref-type="table"}. There was no evidence that *C*~max~ of any of the drugs individually was associated with QTcF at month 1 ([Table 5](#T5){ref-type="table"}).

###### 

*C*~max~, *T*~max~, and AUC at steady state for each drug, by study arm (*n* = 291)

  Drug and parameter at steady state   Median (minimum to maximum) for study arm:   Estimated gradient (95% CI), *P* value[^*a*^](#T5F1){ref-type="table-fn"}   
  ------------------------------------ -------------------------------------------- --------------------------------------------------------------------------- ----------------------------
  Gatifloxacin                                                                                                                                                  
      *C*~max~                         3.8 (2.5--5.8)                               NA[^*b*^](#T5F2){ref-type="table-fn"}                                       −3.82 (−11.78, 4.14), 0.34
      *T*~max~                         1.7 (0.8--3.6)                               NA                                                                          NA
  Ethambutol                                                                                                                                                    
      *C*~max~                         NA                                           3.2 (1.5--5.5)                                                              −1.99 (−5.96, 1.98), 0.32
      *T*~max~                         NA                                           2.5 (1.5--4.5)                                                              NA
  Isoniazid                                                                                                                                                     
      *C*~max~                         3.1 (0.7--8.0)                               3.1 (0.5--6.0)                                                              0.86 (−1.11, 2.83), 0.39
      *T*~max~                         0.9 (0.6--3.2)                               0.8 (0.3--3.6)                                                              NA
  Rifampin                                                                                                                                                      
      *C*~max~                         6.3 (1.4--13.2)                              6.9 (2.0--15.6)                                                             0.16 (−1.08, 1.39), 0.81
      *T*~max~                         2.2 (1.3--5.6)                               1.9 (1.1--5.3)                                                              NA
  Pyrazinamide                                                                                                                                                  
      *C*~max~                         35.9 (23.8--60.4)                            35.0 (21.9--62.1)                                                           −0.28 (−0.66, 0.10), 0.15
      *T*~max~                         1.7 (0.9--4.5)                               1.5 (0.8--5.0)                                                              NA

For the association of each drug *C*~max~ individually on QTcF at month 1, adjusted for country, sex, age, and QTcF at enrollment, and study arm (only for isoniazid, rifampin, and pyrazinamide). CI confidence interval.

NA, not applicable.

DISCUSSION {#sec3}
==========

This study shows that the risk of QT prolongation with either a 4-month regimen including gatifloxacin or a standard 6-month treatment is low: only five (0.6%) and four (0.5%) subjects, respectively, had a value of \>500 ms, and 7% and 6.3%, respectively, had a prolongation relative to their baseline value of \>60 ms.

We also found that in this African population with active PTB, the Bazett formula QTcB (QT/RR^0.5^) undercorrects and the Fridericia formula QTcF (QT/RR^0.33^) overcorrects QT as RR increases; the QTcTB (QT/RR^0.4081^) best fits this population. For instance, screening patients for values of \>480 ms with the QTcF would have missed 1 of the 2 cases, and the QTcB would have excluded 3 more cases. While the TB correction factor appears to benefit subjects of both sexes in all the countries of this study, it will be important to verify the appropriateness of this correction on larger and more diverse TB patient populations. This may have implications for entry criteria when recruiting into a TB treatment trial, as well as measuring relative changes in the QT after treatment. As patients on treatment recover, the Fridericia formula becomes more appropriate, and QTcB and QTcTB overestimate the prolongation (with 11, 13, and 8 cases having QTcB and 2, 3, and 3 cases having QTcTB of \>480 ms at week 4, week 8, and end of treatment, respectively). The correction factor is introduced to make the QT independent of the heart rate, which translates to the regression lines displayed in [Fig. 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"} for corrected QTc; the slope is closest to zero (a horizontal line) when using the population-specific QTcTB.

ECGs were done before starting and during antituberculosis treatment. During treatment, the ECGs were done 1 to 5 h postdosing (corresponding to the interval when drug concentrations are expected to be highest in plasma) at months 1 and 2 and at the end of treatment (month 4 for the gatifloxacin-containing regimen or month 6 for standard treatment). These measurements occurred when drug concentrations were at steady state, and patients were improving or convalescent.

It is becoming increasingly clear that, while FQs are generally known to block the inward delayed rectifier current I~Kr~ through the potassium channel, QT prolongation and TdP risk cannot be considered a class effect, as the individual FQ affinities for the hERG-I~Kr~ receptor (both in absolute terms and relative to plasma levels) vary widely.

*In vitro*, gatifloxacin had a 50% inhibitory concentration (IC~50~) of 130 μM (48.8 μg/ml) for the hERG channel I~Kr~ with blocking activities for other quinolones ranging from 18 μM (sparfloxacin) as the most active to 1,420 μM (ofloxacin) as the least active quinolone ([@B4]). A similar range of blocking activities for I~Kr~ has been determined in the mouse tumor cell line AT-1, with IC~50~s of 0.23 μM (sparfloxacin), 26.5 μM (gatifloxacin), and 27.2 μM (grepafloxacin) ([@B8]). The influence of a series of fluoroquinolones on action potential duration (APD) was also studied in isolated guinea pig right ventricular myocardia: while some of the drugs tested did not influence APD, gatifloxacin increased the APD by 13% at a concentration of 100 μM (37.5 μg/ml); at the same concentration, sparfloxacin increased the APD by 41%, while grepafloxacin and moxifloxacin showed intermediate values of 24% and 25%, respectively ([@B9]).

All the FQs tested showed propensities for a prolongation of the QT and/or the QTc interval (Carlsson correction, QT − 0.175 \[RR − 300\]) in an *in vivo* anesthetized rabbit model. The compounds were infused intravenously at a dose of 2 mg/kg of body weight/min for 30 min, with sparfloxacin producing the highest absolute QT prolongation (+129 ms from baseline); gatifloxacin showed a minimal prolongation of the QT interval (increase from baseline, 14 ms). Ventricular tachycardia and TdP were elicited only by sparfloxacin and only when the infusion was extended to a duration of 60 min ([@B8]). A similar model in rabbits using intravenous infusion doses of 4 mg/kg/min yielded QT and QTc interval prolongation values for gatifloxacin similar to those of sparfloxacin, with increases in interval times from about 160 ms at baseline to about 320 ms at 30 min after the start of the infusion ([@B10]).

In order to put the nonclinical data into perspective, these concentrations that evoke cardiac effects in experimental *in vitro* and *in vivo* models must be compared to plasma levels achieved in patients. According to the Tequin (gatifloxacin) label, a 400-mg intravenous bolus given to healthy volunteers leads to a *C*~max~ of ∼5.5 μg/ml, a concentration which is ∼23 times lower than the IC~50~ for hERG inhibition and ∼5-times lower than the IC~50~ for I~Kr~ blockade in AT-1 cells; in this phase 3 trial (oral treatment with 400 mg/day), the *C*~max~ was 3.9 μg/ml after the first dose and 3.8 μg/ml at steady state (IC~50~/*C*~max~ ratio, ∼34 \[95% CI, 21 to 54\]). Both indicate a substantially lower risk than that inferred by Kang et al. ([@B4]). In addition, when applying a scaling factor of 0.324 for the dose administered to extrapolate the *in vivo* rabbit data to humans, the intravenous infusion of 2 mg/kg/min, resulting in only a minimal prolongation of the QT interval, will then correspond to a human-equivalent bolus dose of ∼20 mg/kg, or 1,000 mg for a 50-kg human. Similarly, the FDA data for Tequin in mongrel dogs, where no influence on the ECG was seen at an intravenous infusion of 10 mg/kg/min, can be translated into a human-equivalent bolus dose of ∼162 mg/kg, or a dose of \>8,000 mg. All these data suggest a low risk for gatifloxacin to induce serious cardiovascular adverse events.

Furthermore, there is no clear correlation between hERG-I~Kr~ receptor affinity and risk of QT prolongation or risk of TdP. The risk of TdP with FQs is in actual fact very low and is estimated to be at ∼27 for 10 million prescriptions for gatifloxacin, including subjects with concomitant risk factors ([@B11]). The Uppsala Monitoring Centre database reports as of 1 March 2014 a total of 13,556 cardiac adverse events with fluoroquinolones, of which 767 are QT prolongation and 451 are TdP: 100 and 53, respectively, with gatifloxacin; 207 and 166, respectively, with levofloxacin; and 269 and 113, respectively, with moxifloxacin. Direct comparisons are obviously not possible due to the absence of the denominator (number of people exposed to the different FQs).

The main methodological limitation of this study is that there was no external review of QTc measurement, but all were measured automatically with the same machine in all study sites, and all QTc values reported in the case record form (CRF) were reviewed by an external monitor; furthermore, there was only one QTc measurement done at each time point. Another potential limitation is that, assuming that *C*~max~ is the main determinant of the risk for QT prolongation, ECGs were done during treatment when all drugs were at steady state, but peak plasma concentrations might have been higher in the earlier phases of treatment.

In summary, this study indicates that neither a standard 6-month TB treatment nor a 4-month, 6-day-a-week regimen including gatifloxacin at 400 mg/day in combination with three (rifampin, isoniazid, and pyrazinamide) other antituberculosis drugs for the first 2 months and two (rifampin and isoniazid) for the following 2 months appears to carry a sizable risk of QT prolongation.

These results are significant and novel for a number of reasons. To our knowledge, this is to date the largest data set studying the QT interval during acute active tuberculosis itself, documenting the effects on the QT interval of the standard regimen as well as a fluoroquinolone-containing regimen and investigating the relationship between drug levels and the QT. As such, the data fill a knowledge gap and are useful for future studies. It will be important to verify in other sets of patients, including those with other forms of tuberculosis, whether and how active disease affects the QT interval and which formula is best suited to correct it so as to make it independent of the heart rate. This knowledge will improve also our understanding of treatment effects, as it will refine the classification of QT values as being normal or prolonged---both for eligibility for treatment and for assessing risks. This study also provides a reference point for other studies which will aim to evaluate the effects on ventricular repolarization of standard and alternative treatments on both newly diagnosed and drug-resistant tuberculosis, as the latter in particular may include drugs with potential for QT prolongation.

MATERIALS AND METHODS {#sec4}
=====================

Study design. {#sec4-1}
-------------

The study was a noninferiority randomized, open-label, controlled trial, conducted in five African countries, Benin, Guinea, Kenya, Senegal, and South Africa, with a nested PK/PD study for a subset of patients. Its objective was to assess the efficacy and safety of a gatifloxacin-containing 4-month regimen for the treatment of drug-susceptible pulmonary tuberculosis compared to standard World Health Organization (WHO)-recommended 6-month treatment ([@B12]). The protocol was approved by the relevant ethics committee and regulatory authorities of all partner institutions. More details on study design have been published elsewhere ([@B7]).

Subjects. {#sec4-2}
---------

Male and female patients, aged 18 to 65 years, newly diagnosed with microscopically proven pulmonary tuberculosis and providing informed consent for inclusion in the trial, were considered for enrollment. Patients with congenital QTc interval prolongation of \>480 ms, clinically significant bradycardia (40 beats/minute), or hypokalemia of grade 1 and above (i.e., \<3.0 meq/liter) and patients using drugs known to prolong QT interval were excluded at enrollment.

Treatment arms. {#sec4-3}
---------------

Patients were randomized, stratified by country, to one of two treatment arms. The control treatment regimen included isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E) given daily for 2 months followed by 4 months with isoniazid and rifampin (i.e., 2RHEZ/4RH). In the intervention arm (referred to as test), gatifloxacin (G) was substituted for ethambutol in the 2-month intensive phase and was maintained for the 2-month continuation phase (i.e., 2RHGZ/2GRH). Gatifloxacin was given at a dose of 400 mg per day, irrespective of body weight. The doses of HRZE followed World Health Organization (WHO) recommendations ([@B12]) and were provided as fixed-dose combination tablets.

Measurements. {#sec4-4}
-------------

Along with clinical and laboratory evaluations, 12-lead electrocardiograms (ECGs) were performed at baseline (pretreatment), at months 1 and 2 of TB treatment, and at the end of the treatment. ECGs were obtained with a Shiller CP300 machine which was configured to report QT intervals automatically and to calculate the corrected QT interval (QTc) by Bazett\'s formula. The exact heart rate at the time of ECG measurement was also automatically measured and recorded. This allowed us to calculate *a posteriori* QTc interval using other formulas such as Fridericia\'s formula. The following information was also recorded for each patient: gender, age, medical history, vital signs (including body temperature), clinical examination, and concomitant medication.

Plasma samples were taken for drug concentration measurements at baseline and month 1 as part of a population PK study. Patients were randomized to one of three sampling schedules (A, B, and C), each with three sampling times: schedule A, sample 1, within the hour before the treatment dose (−1 to 0 h); sample 2, between 1 and 2 h after the treatment dose; and sample 3, between 2.5 and 3.5 h after the treatment dose; schedule B, sample 1, between 1 and 2 h after the treatment dose; sample 2, between 2.5 and 3.5 h after the treatment dose; and sample 3, between 4 and 6 h after the treatment dose; and schedule C, sample 1, between 1 and 2 h after the treatment dose; sample 2, between 2.5 and 3.5 h after the treatment dose; and sample 3, between 8 and 10 h after the treatment dose.

Population pharmacokinetic models were used to generate individual estimates of peak drug concentration (*C*~max~) and time to *C*~max~ (*T*~max~) at steady state ([@B13], [@B14]).

Drug safety was closely monitored during the course of the study in compliance with ICH/good clinical practice (GCP) guidelines.

Statistical methods. (i) Review of the correction factor. {#sec4-5}
---------------------------------------------------------

The QT measurement at enrollment, combined across treatment arm, was used to assess the correction factor in this sample of TB patients. We calculated the linear regression coefficients of gradient and intercept for the Bazett-corrected (correction factor RR^0.5^) and Fridericia-corrected (correction factor RR^0.33^) QT against 1-RR. These analyses were repeated for each measurement postrandomization---month 1, month 2, and at the end of treatment (either month 4 or month 6 for the test and control arms, respectively)---combined across treatment arm for the purpose of assessing the adequacy and robustness of the correction factors.

In addition, a nonlinear model was fitted to the uncorrected QT at baseline to estimate the population-specific correction factor for the pretreatment patients with active pulmonary tuberculosis.

(ii) Definition of outcomes. {#sec4-6}
----------------------------

According to ICH guidelines ([@B6]), QTc data are presented as both continuous and binary variables using the Fridericia correction (QTcF). Continuous measurements were summarized using the arithmetic mean and standard deviation (SD). Peak QTc was defined as the maximum QTc interval from up to a possible 3 follow-up recordings (week 4 or 8 or end of treatment).

(iii) Between-treatment arm comparisons. {#sec4-7}
----------------------------------------

Peak QTcF during follow-up and change of this measurement from baseline were compared between treatment arms using linear regression, adjusting for country where possible. Peak values were also classed as binary variables using cut points at \>450 ms, \>480 ms, and \>500 ms and change from baseline as \>60 ms; between-treatment comparisons were expressed as risk difference, adjusted for country. Patients with a baseline measurement and at least one follow-up measurement contributed to these analyses.

(iv) PK/PD analysis. {#sec4-8}
--------------------

In the subset of patients who had drug concentration measurements, the effect of *C*~max~, for each drug separately, on QTcF at month 1 was assessed using linear regression, adjusting for country, sex, age, and QTcF at enrollment, and study arm (adjusting for study arm only for the effect of *C*~max~ for isoniazid, rifampin, and pyrazinamide).
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